Calcium Phosphate and Incretins

NCT ID: NCT01296997

Last Updated: 2012-11-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-07-31

Study Completion Date

2010-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study was conducted to investigate the effect of a calcium phosphate supplementation on the secretion of incretins.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Men

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

calcium phosphate incretins human study

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

calcium phosphate

Group Type EXPERIMENTAL

calcium phosphate

Intervention Type DIETARY_SUPPLEMENT

the subjects consumed for 3 weeks a bread enriched with 1 g pentacalcium phosphate per day

placebo

Group Type PLACEBO_COMPARATOR

placebo

Intervention Type OTHER

the subjects consumed a bread without pentacalcium phosphate

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

calcium phosphate

the subjects consumed for 3 weeks a bread enriched with 1 g pentacalcium phosphate per day

Intervention Type DIETARY_SUPPLEMENT

placebo

the subjects consumed a bread without pentacalcium phosphate

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* healthy men

Exclusion Criteria

* intake of dietary supplements and chronic diseases
Minimum Eligible Age

20 Years

Maximum Eligible Age

35 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Jena

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Gerhard Jahreis

Prof. Dr. habil

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Gerhard Jahreis, Prof. Dr.

Role: PRINCIPAL_INVESTIGATOR

Friedrich-Schiller-University Jena, Institute of Nutrition, Department of Nutritional Physiology

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Friedrich-Schiller-University Jena, Institute of Nutrition, Department of Nutritional Physiology

Jena, Thuringia, Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany

References

Explore related publications, articles, or registry entries linked to this study.

Trautvetter U, Kiehntopf M, Jahreis G. Postprandial effects of calcium phosphate supplementation on plasma concentration-double-blind, placebo-controlled cross-over human study. Nutr J. 2013 Mar 8;12:30. doi: 10.1186/1475-2891-12-30.

Reference Type DERIVED
PMID: 23510513 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

LSEP H45-10

Identifier Type: -

Identifier Source: org_study_id